BREAKING: IBM Watson AI XPRIZE announces Aifred Health as Top 3 Global Finalist in world’s largest AI competition.

About Us

Aifred is focused on clinical decision support in mental healthcare, starting with depression. Depression affects over 300 million people worldwide. Physicians currently have few tools to help them effectively select and manage mental health treatments based on the unique characteristics of their individual patients leading to an arduous and lengthy “trial and error” approach to treatment. Aifred operationalizes best-evidence guidelines, together with AI-based insights, to support better treatment management, and matching of individual patients to the right treatment.

Aifred plans to encompass a broad spectrum of mental health conditions, leveraging their treatment-agnostic AI model. At its core, Aifred is focused on bringing better mental healthcare to all.

We are a proud official IBM Watson AI XPRIZE semi-finalist team, headquartered in Montreal, Canada.

Read more about us:

Use of AI

Aifred uses AI to accomplish what was previously not possible with other methods: helping clinicians and patients make better treatment choices as they are faced with a large number of treatments options that are all similarly effective at the population level, but not at the individual patient level. Along with a network of domain experts in psychiatry, we are harnessing the power of AI to identify patterns in patient data that can predict optimal personal treatment.

Aifred is also innovating in the area of clinical interpretability, to reduce the ‘black box’ nature of deep learning models and to provide physicians and patients with the rationale for the AI’s treatment recommendation.

Quality of model predictions are very important and we analyze this carefully, making sure to take only the best models to clinical practice. By training our predictive models on high-quality and reliable clinical datasets, we ensure quality input to our model. De-identified patient outcomes collected by our tool over time will feed back into our neural networks to continuously improve Aifred’s predictive power.

Our Product

Our solution uses AI to learn from the clinical data of thousands of patients to help tailor individual treatment, significantly reducing the time it takes for a patient to reach remission. Specifically, we use deep learning to perform differential treatment selection, which allows us to capture complex relationships within patient data. We have built a clinician-patient application that allows patients to answer questionnaires about their mental state and quality of life, and visualizes this data for both the patient and clinician while providing key decision support for treatment.

Treatment Prediction

The Aifred solution makes use of innovative and powerful machine learning techniques to predict treatment efficacy based on an array of individual patient characteristics.

Clinical Treatment Algorithm

Our solution includes a clinical treatment algorithm based on best-practice guidelines, which, combined with the ability to collect patient input, allows for easy implementation of gold-standard measurement-based care.

Measurement-Based Care

Track patient symptoms and test results to monitor outcomes or make new predictions. Banks of standardized questionnaires, data visualization, -- all of it capable of being tailored to clinicians' needs.


Our system provides a report to highlight the most significant features that lead to a personalized treatment prediction, enabling the clinician to understand what is behind the information provided and avoiding a “black-box” recommendation from our AI system.

From Fundamental to Clinical


Our team is conducting leading research into new interpretability techniques and into further improving our differential treatment benefit prediction. Our researchers have also conducted in-depth research to identify predictors of treatment response and side effect burden in depression including examining the potential feasibility of adding biomarker testing in routine clinical practice, although our tool is not dependent on such input today.


Clinical research is focused on validating our model in controlled and real-world conditions. We are running pilots of our current product at three hospital sites in Canada and have also tested our product with the AI included, in a simulation center environment. Now we are beginning the first ever clinical studies of an AI-powered clinical decision support system in depression that does not rely on inputs from additional tests. We are blazing the trail when it comes to clinical validation of deep-learning based clinical decision aids, and as such are investing heavily in the development of ethical principles to guide development and testing and in ensuring safety and useability of our tools. In fact, ethical development is so important to us that we have created our own ethical framework, known as Meticulous Transparency, to guide our work.


We strongly believe in the potential for AI to enhance, but never replace, physician decision-making. Following this principle, the model must be user-friendly and provide clinicians and patients with features they want and need. Initial studies have shown that the majority of clinicians who tried it trust our tool to help them make decisions, and 90% of clinicians say they would use it with their patients who are most in need.

Open Label Trials

Safety and effectiveness of the AI model must be rigorously assessed in an open-label clinical trial. A group of physicians using our model will be compared to a group practicing usual care, and patient outcomes will be evaluated. We have applied for and received approval from Health Canada to conduct this clinical trial and will be meeting with the US FDA to seek approval to conduct our trial in the United States.

Careers at Aifred Health

Join our world class team to change the world!


Dr. Gustavo Turecki, MD, PhD - Genetics, Dataset Access Content Expert
Dr. Marc Miresco, MD, MSc - External Psychiatry Services Content Expert
Dr. Gail Myhr, MDCM, Dip Psy, MSc, FRCP - Cognitive Behavioral Therapy Content Expert
Dr. Marcelo Berlim, MD, MSc - Literature Review and Neuromodulation Content Expert
Dr. Howard Margolese MD, CM, MSc, FRCPC - Clinical Trial Expert

Dr. Daniel Blumberger, MD, MSc, FRCPC - rTMS and NeuromodulationContent Expert
Dr. Simone Vigod, MD, MSc, FRCPC - Guidelines, Best Practices,Cultural Safety Content Expert

Dr. Sagar Parikh, MD - Guidelines, Best Practices, Cultural SafetyContent Expert

Tristan Sylvain - Machine Learning Content Expert
Dr. MargauxLuck - Machine Learning Content Expert

Dr. Wendell Wallach - Bioethics and AI Ethics Content Expert

Dr. Jordan Karp, MD - Late Life Depression Content Expert

Dr. Ann John, PhD, Suicide and Epidemiology Content Expert
Dr.Marcos Del Pozo Baños, PhD, Machine Learning and Medical Records Content Expert

Tung Tran, Director of Mental Health and Addiction Programs

Aifred in the news

AIFRED HEALTH closes $4 million seed financing to improve mental health

New app helps family doctors track patients’ mental health in greater detail

App helps family doctors track patients’ mental health

AIFRED HEALTH Sole Candaian Team Among 10 Semi-finalists of Global IBM Watson Competition

AI App Helps Tailor Mental Health Treatment

5 Entrepreneurs On The Rise In AI

AIFRED HEALTH: Personalized Psychiatry

Montreal start-up AIFRED HEALTH is applying AI to mental healthcare

Montreal startup develops AI tool to improve depression treatment

Get in touch!